Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.

Endocrine, metabolic & immune disorders drug targets - 1 Mar 2010

Zoubir Moustapha, Tursz Thomas, Ménard Cédric, Zitvogel Laurence, Chaput Nathalie

Abstract excerpt

The treatment against cancer is being flooded by targeted therapies. Imatinib mesylate (Gleevec) was the first molecule to provide the proof of principle that targeting an aberrant tyrosine kinase responsible for the uncontrolled cell cycle progression allows for the eradication of tumors. The ideal targeted therapy should eliminate the molecular event responsible for the disease, an oncogenic product such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dendritic Cells
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunomodulation

Share to Interferons

Share to Killer Cells, Natural

Share to Piperazines

Share to T-Lymphocytes, Regulatory

Source

Identifiers

PMID: 19839938
DOI: 10.2174/187153010790827993

Genes

BCR
KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.PMID 19839938Read ↗

Imatinib: the promise of a "magic bullet" for cancer fulfilled.Semantic proximity Read ↗

Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.Semantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.Semantic proximity Read ↗

The BCR-ABL Story: Bench to Bedside and BackSemantic proximity Read ↗

c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571)Semantic proximity Read ↗

[STI571: a summary of targeted therapy].Semantic proximity Read ↗

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.Semantic proximity Read ↗

Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.Semantic proximity Read ↗

Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.Semantic proximity Read ↗

Specific Targeted Therapy of Chronic Myelogenous Leukemia with ImatinibSemantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.